Dupixent is the first new targeted therapy to receive FDA-approval for chronic spontaneous urticaria in adults and ...

Milan Kalawadia, CEO, North America, at Dr. Reddy’s Laboratories, goes inside the company’s new growth initiatives—and ...

Regulatory action was based on data from the Phase III QUASAR trial, which demonstrated that Eylea HD dosed every eight weeks ...

Ted Sweetser discusses how more accurate datasets are solving problems related to getting communities access to better healthcare.

A new study found that patients with type 2 diabetes treated with GLP-1 receptor agonists and sodium-glucose cotransporter-2 ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, explores the potential synergy between myopathies and obesity ...

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

Nigel McCracken, chief operating officer, Virax Biolabs, discusses new findings that reveal altered cytokine activity and ...

How is artificial intelligence shaking up the pharma marketing space? Ted Sweetser: The first top level one that everyone is ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses getting JUV-161 into Phase I trials this year.

Sonam Dubey, a partner at Beghou Consulting, discusses the potential impact of a possible ban on direct-to-consumer ...

Commerce Secretary Lutnick discussed the state of the tariffs in the wake of President Trump’s comments on the pharmaceutical ...